Liu Q‐Q, Sun H‐F, Yang X‐L, et al. Survival following radiotherapy in young women with localized early‐stage breast cancer according to molecular subtypes. Cancer Med. 2019;8:2840--2857. 10.1002/cam4.2186 31016890

Qi‐Qi Liu and He‐Fen Sun contributed equally to this work.

**Funding information**

This work was supported by the grant from National Natural Science Foundation of China (81773093) and a Municipal Human Resources Development Program for Outstanding Leaders in Medical Disciplines in Shanghai (2017BR028).

1. INTRODUCTION {#cam42186-sec-0005}
===============

Breast cancer is one of the most common cancers and the second leading cause of cancer death among women in the United States. Breast cancer is identified as having increased prevalence at younger ages and increased mortality rates for these years.[1](#cam42186-bib-0001){ref-type="ref"}, [2](#cam42186-bib-0002){ref-type="ref"} Approximately 11% of breast cancer women patients are diagnosed at age younger than 45 years.[3](#cam42186-bib-0003){ref-type="ref"} Compared with older counterparts, they are often accompanied by worse outcome, increased locoregional recurrence rate,[4](#cam42186-bib-0004){ref-type="ref"} and poorer treatment response owing to its more aggressive behaviors.[5](#cam42186-bib-0005){ref-type="ref"}, [6](#cam42186-bib-0006){ref-type="ref"} The Breast Cancer Education and Awareness Requires Learning Young (EARLY) act and prior research have identified woman under the age of 45 years to be particularly burdened by breast cancer.[7](#cam42186-bib-0007){ref-type="ref"}, [8](#cam42186-bib-0008){ref-type="ref"} In addition, researchers investigated that breast cancer women patients younger than 45 years are correlated with higher‐than‐expected frequencies of BRCA mutations, which are associated with an 50%‐85% elevated lifetime risk for breast cancer.[9](#cam42186-bib-0009){ref-type="ref"}, [10](#cam42186-bib-0010){ref-type="ref"} Radiotherapy (RT) could reduce recurrence risks, improve local control, and prolong overall survival (OS) which plays an indispensable role in the treatment for invasive breast cancer patients.[11](#cam42186-bib-0011){ref-type="ref"}, [12](#cam42186-bib-0012){ref-type="ref"}

Breast cancer is classified into four major subgroups according to hormone receptors (HoR) and human epidermal growth factor receptor 2 (HER2) status, namely luminal‐A, luminal‐B, HER2‐enriched, and triple‐negative subtypes.[13](#cam42186-bib-0013){ref-type="ref"}, [14](#cam42186-bib-0014){ref-type="ref"} The heterogeneous of subgroups has substantial influence on survivals and recurrence risks of breast cancer. Studies have investigated correlations between subtypes and response to different treatment strategies including chemotherapy, targeted therapy, and endocrine therapy in breast cancer. However, despite the majority of young patients with localized early‐stage breast cancer receiving radiotherapy, the effect of HoR and HER2 status on benefit of RT in early‐stage breast cancer has not been integrated much.[15](#cam42186-bib-0015){ref-type="ref"} Thus, this is the first study comparing the RT benefit in young women with localized early stage breast cancer according to molecular subtypes, which could help predicting RT response and improve patient\'s survival by adjusting treatment strategies for individuals in the future.

2. MATERIALS AND METHODS {#cam42186-sec-0006}
========================

2.1. Ethics statement {#cam42186-sec-0007}
---------------------

The Surveillance, Epidemiology, and End Results (SEER) research data were obtained using the reference number 14684‐Nov2017. Informed consent is not required. Our study was in accordance with the ethical standards of Fudan University Shanghai Cancer Center (FDUSCC) and 1964 Helsinki Declaration. The methods were carried out according to the approved guidelines.

2.2. Study participants {#cam42186-sec-0008}
-----------------------

We collected data of 23 148 patients using SEER\*Stat (version 8.3.5), which reported cases from 18 population‐based registries (1973‐2013) on demographic characteristics including age, race, year of diagnosis, as well as laterality, grade, histology, TNM stage, ER, PR and HER2 status, tumor size, survivals and treatment strategies of patients in the United States. This analysis was limited to 18‐45 female patients, and diagnosed with stage T1‐3, N0‐3, M0 early‐stage breast cancer (American Joint Committee on Cancer \[AJCC\] stages I‐IIIC) between 2010 and 2013. The designation of "young women" with the 18‐45 age range was selected based on common clinical practices and previous researches.[16](#cam42186-bib-0016){ref-type="ref"}, [17](#cam42186-bib-0017){ref-type="ref"} All patients had complete information regarding the receipt of radiotherapy. Patients with ER and PR borderline were excluded for the accuracy of results. Patients were categorized according to their race (white, black, others, or unknown), age (18‐40 or 41‐45 years), laterality (left, right, bilateral, or unknown), tumor size (≤2 cm, 2‐5 cm, \>5 cm, or unknown), breast‐adjusted AJCC sixth T (T1, T2, or T3), breast‐adjusted AJCC sixth N (N01, N1, N2, or N3), breast‐adjusted AJCC sixth stage (I, IIA, IIB, IIIA, or IIIC), grade (I, II, III, IV, or unknown), ER, PR, and HER2 status (positive or negative), and radiotherapy (yes or no). For molecular phenotyping, we defined HoR + as ER + and/or PR+, and HoR‐ as ER‐PR‐, while grouped tumors into four categories: luminal‐A (HoR+/HER2‐), luminal‐B (HoR+/HER2+), HER2‐enriched (HoR‐/HER2+), and triple‐negative (HoR‐/HER2‐).[18](#cam42186-bib-0018){ref-type="ref"}, [19](#cam42186-bib-0019){ref-type="ref"} Patients diagnosed before 2010 were excluded since the HER2 status and molecular subtype information were not available.

2.3. Statistical analysis {#cam42186-sec-0009}
-------------------------

The clinicopathological characteristics among different subgroups were compared using the Pearson\'s *χ* ^2^ test. Breast cancer‐specific survival (BCSS) and OS were defined as the time from diagnosis to death due to breast cancer and any cause, respectively. Kaplan‐Meier analysis was performed to generate survival curves. Univariate and multivariate Cox hazard model was utilized to compare the prognostic role of RT in different subgroups, and calculate the HR and 95% CI. Subgroups were dichotomized according to the HoRs, HER2 status and molecular subtypes. Considering the characteristics unbalance between the subgroups, propensity score matching (PSM) was performed. All statistical analyses were performed using SPSS 25.0 software (SPSS, Chicago, IL). *P* \< 0.05 was defined as statistically significant.

3. RESULTS {#cam42186-sec-0010}
==========

3.1. Patient characteristics by molecular subtypes {#cam42186-sec-0011}
--------------------------------------------------

A total of 23 148 young female patients diagnosed with early‐stage breast cancer in 2010‐2013 were enrolled, including 16 966 white patients, 3041 black patients, and 2961 patients of other races. The demographic and clinicopathological characteristics are presented according to molecular subtypes in Table [1](#cam42186-tbl-0001){ref-type="table"}. The median age of patients was 41 years, 10 468 (45.2%) were younger than 40 years and 12 680 (54.8%) were 40‐45 years. Patients diagnosed with luminal‐A, luminal‐B, HER2‐enriched, and triple‐negative breast cancer were 14 708 (63.5%), 3385 (14.6%), 1225 (5.2%) and 3830 (16.5%), respectively. Radiotherapy was performed in 11 985 (51.8%) patients. The majority of patients received surgery (22 310, 96.4%), and nearly half (45.3%) were performed before RT. Eight thousand six hundred and sixty‐eight (37.4%), 7032 (30.4%), 3979 (17.2%), 2618 (11.3%), and 851 (3.7%) patients were diagnosed with stage I, IIA, IIB, IIIA, and IIIC, respectively. Nine thousand five hundred (41.0%) patients had positive lymph node metastasis. The median follow‐up was 22 months in the present study.

###### 

Patient characteristics by molecular subtypes

  Characteristics                   Luminal‐A   Luminal‐B   HER2‐enriched   Triple negative   Total   *P* value                                        
  --------------------------------- ----------- ----------- --------------- ----------------- ------- ----------- ------ ------ ------- ------- ------ -------------
  Race                              White       10941       0.74            2473              0.73    871         0.71   2681   0.70    16966   0.73   **\<0.001**
  Black                             1677        0.11        415             0.12              179     0.15        770    0.20   3041    0.13           
  Others                            1977        0.13        458             0.14              172     0.14        354    0.09   2961    0.13           
  Unknown                           133         0.01        39              0.01              3       0.00        25     0.01   200     0.01           
  Age                               ≤40         6018        0.41            1760              0.52    659         0.54   2031   0.53    10468   0.45   **\<0.001**
  41‐45                             8690        0.59        1625            0.48              566     0.46        1799   0.47   12680   0.55           
  Year of diagnosis                 2010        3506        0.24            819               0.24    298         0.24   931    0.24    5554    0.24   **0.035**
  2010                              3787        0.26        786             0.23              309     0.25        1022   0.27   5904    0.26           
  2010                              3686        0.25        851             0.25              319     0.26        917    0.24   5773    0.25           
  2010                              3729        0.25        929             0.27              299     0.24        960    0.25   5917    0.26           
  Laterality                        Left        7302        0.50            1699              0.50    606         0.49   1970   0.51    11577   0.50   0.315
  Right                             7405        0.50        1684            0.50              619     0.51        1858   0.49   11566   0.50           
  Bilateral                         0           0.00        1               0.00              0       0.00        1      0.00   2       0.00           
  Unknown                           1           0.00        1               0.00              0       0.00        1      0.00   3       0.00           
  Differentiation                   Grade I     2903        0.20            142               0.04    16          0.01   35     0.01    3096    0.13   **\<0.001**
  Grade II                          6811        0.46        1253            0.37              249     0.20        353    0.09   8666    0.37           
  Grade III                         4486        0.31        1825            0.54              868     0.71        3270   0.85   10449   0.45           
  Grade IV                          35          0.00        17              0.01              14      0.01        39     0.01   105     0.00           
  Unknown                           473         0.03        148             0.04              78      0.06        133    0.03   832     0.04           
  Histologic                        Duct        11937       0.81            3072              0.91    1133        0.92   3506   0.92    19648   0.85   **\<0.001**
  Lobular                           1157        0.08        54              0.02              6       0.00        19     0.00   1236    0.05           
  Duct &lobular                     882         0.06        121             0.04              13      0.01        45     0.01   1061    0.05           
  Others                            732         0.05        138             0.04              4       0.00        260    0.07   1134    0.05           
  TNM stage                         I           6124        0.42            1123              0.33    383         0.31   1038   0.27    8668    0.37   **\<0.001**
  IIA                               4249        0.29        1017            0.30              341     0.28        1425   0.37   7032    0.30           
  IIB                               2310        0.16        667             0.20              217     0.18        785    0.20   3979    0.17           
  IIIA                              1564        0.11        445             0.13              195     0.16        414    0.11   2618    0.11           
  IIIC                              461         0.03        133             0.04              89      0.07        168    0.04   851     0.04           
  T                                 T1          8227        0.56            1584              0.47    557         0.45   1401   0.37    11769   0.51   **\<0.001**
  T2                                5283        0.36        1460            0.43              479     0.39        1972   0.51   9194    0.40           
  T3                                1198        0.08        341             0.10              189     0.15        457    0.12   2185    0.09           
  N                                 N0          8848        0.60            1843              0.54    627         0.51   2330   0.61    13648   0.59   **\<0.001**
  N1                                4355        0.30        1133            0.33              405     0.33        1098   0.29   6991    0.30           
  N2                                1044        0.07        276             0.08              104     0.08        234    0.06   1658    0.07           
  N3                                461         0.03        133             0.04              89      0.07        168    0.04   851     0.04           
  Radiation                         No          7507        0.51            1760              0.52    656         0.54   2062   0.54    11985   0.52   **0.01**
  Yes                               7201        0.49        1625            0.48              569     0.46        1768   0.46   11163   0.48           
  Radiation type                    None        7507        0.51            1760              0.52    656         0.54   2062   0.54    11985   0.52   **0.001**
  Beam                              7061        0.48        1608            0.48              557     0.45        1742   0.45   10968   0.47           
  Radioactive implant               62          0.00        4               0.00              3       0.00        5      0.00   74      0.00           
  Isotopes                          0           0.00        0               0.00              0       0.00        2      0.00   2       0.00           
  Beam with implants/isotopes       11          0.00        3               0.00              0       0.00        3      0.00   17      0.00           
  Unknown                           67          0.00        10              0.00              9       0.01        16     0.00   102     0.00           
  Radiation sequence with surgery   None        7507        0.51            1760              0.52    656         0.54   2062   0.54    11985   0.52   **\<0.001**
  Prior to surgery                  29          0.00        11              0.00              9       0.01        15     0.00   64      0.00           
  Intraoperative                    39          0.00        7               0.00              1       0.00        3      0.00   50      0.00           
  After surgery                     7085        0.48        1593            0.47              546     0.45        1734   0.45   10958   0.47           
  Others                            48          0.00        14              0.00              13      0.01        16     0.00   91      0.00           
  Surgery                           No          324         0.02            101               0.03    46          0.04   151    0.04    622     0.03   **\<0.001**
  Yes                               14279       0.97        3242            0.96              1162    0.95        3627   0.95   22310   0.96           
  Unknown                           105         0.01        42              0.01              17      0.01        52     0.01   216     0.01           
  Tumor size                        ≤2          8232        0.56            1588              0.47    560         0.46   1403   0.37    11783   0.51   **\<0.001**
  2‐5                               5318        0.36        1468            0.43              489     0.40        1980   0.52   9255    0.40           
  \>5                               1139        0.08        326             0.10              173     0.14        446    0.12   2084    0.09           
  Unknown                           19          0.00        3               0.00              3       0.00        1      0.00   26      0.00           

P value was calculated among all groups by the Chi‐square test, and a bold type indicates significance.
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Owing to the large sample size of our study, significant differences existed in clinical characteristics including race, age, differentiation, histologic, TNM stage, radiation type, surgery, and tumor size. Among the four molecular subgroups, luminal‐A patients presented with an older age (41‐45 years: 59.1% vs 48.0%, 46.2%, and 48.0% respectively; *P* \< 0.001) and a lower differentiation degree (grade I: 19.7% vs 4.2%, 1.3% and 0.9%, respectively; *P* \< 0.001). HER2‐enriched and triple‐negative patients were more likely to be grade III compared to luminal‐A and luminal‐B patients (70.8% and 85.4% vs 30.5% and 53.9%; *P* \< 0.001). Luminal‐B and HER2‐enriched patients had more advanced tumors (tumor size \>5 cm: 14.1% and 11.6% vs 7.7% and 9.6%, respectively; *P* \< 0.001) than luminal‐A and triple‐negative patients. The incidence of lymph node metastasis (N3: 7.3% vs 3.1%, 3.9% and 4.4%, respectively; *P* \< 0.001) and percentage of IIIA stage (15.9% vs 10.6%, 13.1% and 11.8%, respectively; *P* \< 0.001) was higher in the HER2‐enriched patients than in the luminal‐A, luminal‐B and triple‐negative. No difference was found among subgroups at year of diagnosis and laterality.

3.2. Comparison of OS and BCSS among the study population {#cam42186-sec-0012}
---------------------------------------------------------

The Cox hazard models were conducted to evaluate effects of important characteristics on OS and BCSS in breast cancer patients. Without adjusting for confounding factors, univariate analysis indicated that black race, 41‐45 years of age, duct carcinoma, higher T and N stage, higher degree of differentiation and larger tumor size were associated with a worse overall survival, and a higher risk of death from breast cancer. However, age, T stage and tumor size were no longer distinctly correlated with prognosis in the adjusted multivariate model. Multivariate analysis results showed that RT was an independent prognostic factor for young early‐stage breast cancer patients. Compared to controlled groups, patients received RT had prolonged OS (HR: 0.717, 95% CI: 0.61‐0.844, *P* \< 0.001) and BCSS (HR: 0.736, 95% CI: 0.617‐0.878, *P* = 0.001). The results were consistent with Kaplan‐Meier plots. In addition, black race, duct carcinoma, higher N stage, and differentiation degree were significantly associated with worse OS (all *P* \< 0.05). All of the factors above were associated with higher breast cancer‐related mortality (*P* \< 0.05) except duct carcinoma, which exhibited a borderline correlation with higher HR (*P* = 0.066). Results of survival analysis were summarized in Table [2](#cam42186-tbl-0002){ref-type="table"}, and Kaplan‐Meier curves of OS and BCSS by RT groups in the whole early‐stage breast cancer patients are shown in Figure [1](#cam42186-fig-0001){ref-type="fig"}.

###### 

Comparison of overall survival (OS) and breast cancer‐specific survival (BCSS) among the study population

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics     OS        BCSS                                                                                                                                              
  ------------------- --------- -------------- ------------- -------- -------------- ------------- -------- -------------- ------------- ---------- --------------- ------------- ---
  Race                White     ref.                                  ref.                                  ref.                                    ref.                           

  Black               2.083     1.736‐2.50     **\<0.001**   1.659    1.38‐1.993     **\<0.001**   2.038    1.669‐2.488    **\<0.001**   0.673      0.489‐0.927     **0.015**     

  Others              0.685     0.51‐0.921     **0.012**     0.684    0.509‐0.92     **0.012**     0.68     0.494‐0.937    **0.018**     0.477      0.118‐1.921     0.298         

  Unknown             0.747     0.24‐2.326     0.615         0.626    0.201‐1.955    0.421         0.556    0.138‐2.23     0.407         ---                                      

  Age                 ≤40       ref.                                  ref.                                  ref.                                    ref.                           

  41‐45               0.753     0.644‐0.88     **\<0.001**   0.989    0.844‐1.159    0.891         0.683    0.675‐0.81     **\<0.001**   0.908      0.764‐1.080     0.275         

  Year of diagnosis   2010      ref.                                  ref.                                  ref.                                    ref.                           

  2010                1.075     0.891‐1.297    0.448         1.092    0.905‐1.317    0.36          1.096    0.896‐1.341    0.371         1.114      0.91‐1.363      0.294         

  2010                1.123     0.862‐1.462    0.391         1.093    0.838‐1.424    0.512         1.022    0.758‐1.377    0.888         0.974      0.722‐1.314     0.862         

  2010                0.995     0.520‐1.905    0.988         1.01     0.527‐1.937    0.976         0.678    0.267‐1.724    0.415         0.676      0.265‐1.723     0.412         

  Laterality          Left      ref.                                  ref.                                  ref.                                    ref.                           

  Right               0.96      0.821‐1.123    0.613         0.99     0.846‐1.158    0.898         0.91     0.768‐1.079    0.278         0.941      0.793‐1.116     0.483         

  Bilateral           0.002     0‐3.16E + 63   0.938         0.004    0‐4.59E + 53   0.933         0.002    0‐5.11E + 66   0.94          0.001      0‐3.26E + 104   0.958         

  Unknown             48.072    6.74‐343.06    **\<0.001**   31.367   4.253‐231.4    **0.001**     55.977   7.835‐399.9    **\<0.001**   47.927     6.397‐359.1     **\<0.001**   

  Differen\           Grade I   ref.                                  ref.                                  ref.                                    ref.                           
  tiation                                                                                                                                                                         

  Grade II            1.962     1.219‐3.159    **0.006**     1.553    0.962‐2.508    0.072         3.789    1.837‐7.815    **\<0.001**   2.875      1.39‐5.945      **0.004**     

  Grade III           6.843     4.373‐10.71    **\<0.001**   4.142    2.624‐6.540    **\<0.001**   14.897   7.4‐29.99      **\<0.001**   8.529      4.205‐17.30     **\<0.001**   

  Grade IV            5.386     1.841‐15.76    **0.002**     3.534    1.204‐10.37    **0.022**     9.499    2.52‐35.806    **\<0.001**   6.024      1.593‐22.79     **0.008**     

  Unknown             6.742     3.881‐11.71    **\<0.001**   4.737    2.711‐8.277    **\<0.001**   12.831   5.809‐28.34    **\<0.001**   8.533      3.839‐18.96     **\<0.001**   

  Histologic          Duct      ref.                                  ref.                                  ref.                                    ref.                           

  Lobular             0.476     0.294‐0.771    **0.003**     0.546    0.332‐0.899    **0.017**     0.475    0.279‐0.808    **0.006**     0.596      0.344‐1.034     0.066         

  Duct\               0.897     0.61‐1.32      0.582         1.154    0.781‐1.705    0.472         0.98     0.655‐1.465    0.921         1.298      0.864‐1.951     0.209         
  &lobular                                                                                                                                                                        

  Others              1.152     0.836‐1.588    0.388         1.239    0.896‐1.714    0.194         1.062    0.739‐1.528    0.744         1.215      0.842‐1.753     0.298         

  T                   T1        ref.                                  ref.                                  ref.                                    ref.                           

  T2                  2.716     2.24‐3.293     **\<0.001**   3.857    0.255‐58.29    0.33          3.174    2.545‐3.959    **\<0.001**   2066.574   0‐6.10E + 22    0.739         

  T3                  5.985     4.796‐7.467    **\<0.001**   2.234    0.342‐14.60    0.401         7.374    5.757‐9.446    **\<0.001**   2.824      0.421‐18.94     0.285         

  N                   N0        ref.                                  ref.                                  ref.                                    ref.                           

  N1                  1.791     1.483‐2.161    **\<0.001**   1.407    1.158‐1.71     **0.001**     1.95     1.581‐2.405    **\<0.001**   1.47       1.184‐1.825     **\<0.001**   

  N2                  3.007     2.341‐3.861    **\<0.001**   2.154    1.657‐2.802    **\<0.001**   3.512    2.685‐4.594    **\<0.001**   2.365      1.785‐3.133     **\<0.001**   

  N3                  8.188     6.526‐10.274   **\<0.001**   4.993    3.895‐6.401    **\<0.001**   10.019   7.861‐12.77    **\<0.001**   5.649      4.335‐7.361     **\<0.001**   

  Radiation           No        ref.                                  ref.                                  ref.                                    ref.                           

  Yes                 0.982     0.84‐1.148     0.819         0.717    0.61‐0.844     **\<0.001**   1.018    0.859‐1.206    0.84          0.736      0.617‐0.878     **0.001**     

  Tumor size          ≤2        ref.                                  ref.                                  ref.                                    ref.                           

  2 \~ 5              2.694     2.223‐3.265    **\<0.001**   0.461    0.031‐6.922    0.576         3.13     2.511‐3.901    **\<0.001**   0.001      0‐2.77E + 16    0.761         

  \>5                 6.13      4.91‐7.654     **\<0.001**   1.487    0.228‐9.712    0.678         7.574    5.913‐9.703    **\<0.001**   1.316      0.197‐8.798     0.777         

  unknown             3.833     0.536‐27.385   0.181         1.089    0.078‐15.29    0.95          4.891    0.683‐35.04    0.114         1.032      0.071‐14.95     0.982         
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The total CI and *P* value using Cox proportional hazards model and a bold type indicates significance. Abbreviations: HRs, hazard ratios; CI, confidence interval.
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![Kaplan‐Meier curve of overall survival (A) and breast cancer‐specific survival (B) in the whole early‐stage breast cancer patients](CAM4-8-2840-g001){#cam42186-fig-0001}

3.3. Survival analysis in matched groups according to HoR and HER2 {#cam42186-sec-0013}
------------------------------------------------------------------

Since clinicopathological characteristics imbalance existed in the study and RT were not randomly assigned, we performed PSM with a 1:1 nearest‐neighbor method according to HoR and HER2 status to further investigate their effects on the benefit of RT in patients. Kaplan‐Meier analysis was performed to compare survivals between patients with positive and negative HER2 status. As shown in Table [3](#cam42186-tbl-0003){ref-type="table"}, RT was an independent predictor for OS (HR: 0.343, 95% CI: 0.211‐0.558, *P* \< 0.001) and BCSS (HR: 0.372, 95% CI: 0.218‐0.633, *P* \< 0.001) in HER2 + breast patients. In addition, multivariate analysis demonstrated that RT was correlated with significantly prolonged OS and BCSS in the HER2 + patients. However, patients with HER2‐ received no benefit from radiotherapy in OS and BCSS in the adjusted multivariable models.

###### 

Survival analysis in matched groups according to HER2

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics     OS        BCSS                                                                                                                                          
  ------------------- --------- -------------- ----------- -------- --------------- ------------- --------- --------------- ----------- -------- -------------- ------------- ---
  Race                White     ref.                                ref.                                    ref.                                 ref.                          

  Black               1.821     1.133‐2.925    **0.013**   1.712    0.98‐2.991      0.059         1.674     1.037‐2.702     **0.035**   1.299    0.659‐2.56     0.45          

  Others              0.427     0.171‐1.065    0.068       1.397    0.739‐2.639     0.304         0.36      0.144‐0.898     0.028       1.584    0.807‐3.108    0.181         

  Unknown             1.197     0.163‐8.788    0.859       2.343    0.317‐17.31     0.404         1.009     0.138‐7.38      0.993       0.005    0‐1.50E + 17   0.819         

  Age                 ≤40       ref.                                ref.                                    ref.                                 ref.                          

  41‐45               ---                                  1.197    0.769‐1.863     0.425         1.301     0.657‐2.579     0.45        0.817    0.446‐1.498    0.514         

  Year of diagnosis   2010      ref.                                ref.                                    ref.                                 ref.                          

  2010                1.233     0.74‐2.02      0.432       0.769    0.441‐1.341     0.354         1.328     0.814‐2.167     0.256       0.817    0.446‐1.498    0.378         

  2010                1.596     0.765‐3.331    0.213       0.759    0.362‐5.584     0.615         1.349     0.633‐2.879     0.438       0.598    0.215‐1.661    0.324         

  2010                0.011     0‐1.50E + 10   0.754       1.421    0.362‐5.584     0.615         0.033     0‐6.755E + 9    0.797       0.627    0.073‐5.363    0.67          

  Laterality          Left      ref.                                ref.                                    ref.                                 ref.                          

  Right               0.811     0.535‐1.228    0.322       1.748    1.109‐2.755     **0.016**     0.799     0.53‐1.203      0.282       1.785    1.07‐2.978     0.026         

  Bilateral           ---                                  0.011    0‐1.47E + 85    0.965         ---                                   0.01     0‐2.7E + 105   0.971         

  Unknown             ---                                  0.002    0               0.989         ---                                   0.003    0              0.992         

  Differen\           Grade I   ref.                                ref.                                    ref.                                 ref.                          
  tiation                                                                                                                                                                     

  Grade II            0.935     0.379‐2.304    0.884       202.95   0‐4.128E + 10   0.586         0.939     0.323‐2.728     0.908       241.47   0‐9.32E + 11   0.626         

  Grade III           2.004     0.838‐4.792    0.118       232.46   0‐4.714E + 10   0.577         1.995     0.712‐5.591     0.189       235.35   0‐9.06E + 11   0.628         

  Grade IV            0.015     0‐3.11e + 12   0.802       365.22   0‐8.184E + 10   0.548         0.035     0‐1.705E + 7    0.742       480.36   0‐2.02E + 12   0.585         

  Unknown             2.448     0.772‐7.764    0.128       385.06   0‐7.951E + 10   0.542         2.484     0.71‐8.689      0.154       209.67   0‐8.42E + 11   0.636         

  Histologic          Duct      ref.                                ref.                                    ref.                                 ref.                          

  Lobular             0.91      0.28‐2.96      0.875       1.127    0.154‐8.261     0.907         0.882     0.309‐2.52      0.815       1.317    0.179‐9.678    0.787         

  Duct &lobular       2.156     1.068‐4.335    **0.032**   0.742    0.227‐2.43      0.623         1.899     0.897‐4.018     0.094       0.806    0.239‐2.714    0.728         

  Others              0.814     0.296‐2.242    0.691       1.219    0.441‐3.372     0.702         0.86      0.314‐2.355     0.77        1.36     0.422‐4.387    0.607         

  T                   T1        ref.                                ref.                                    ref.                                 ref.                          

  T2                  1.496     0‐5.17E + 33   0.992       1.669    0‐6.908E + 40   0.991         0.711     0‐7.1533 + 40   0.994       1.785    0‐2.42E + 47   0.992         

  T3                  0.013     0‐1.56E + 27   0.899       0.005    0‐6.256E + 31   0.895         0.013     0‐4.57E + 37    0.926       0.006    0‐1.26E + 39   0.916         

  N                   N0        ref.                                ref.                                    ref.                                 ref.                          

  N1                  1.441     0.879‐2.363    0.148       1.316    0.728‐2.382     0.363         1.336     0.815‐2.188     0.251       1.015    0.48‐2.07      0.967         

  N2                  1.266     0.582‐2.755    0.552       3.371    1.672‐6.797     **0.001**     0.912     0.404‐2.059     0.825       3.289    1.512‐7.153    **0.003**     

  N3                  3.203     1.609‐6.375    **0.001**   10.38    5.379‐20.035    **\<0.001**   3.129     1.604‐6.103     **0.001**   12.443   6.103‐25.37    **\<0.001**   

  Radiation           No        ref.                                ref.                                    ref.                                 ref.                          

  Yes                 1.129     0.725‐1.759    0.59        0.343    0.211‐0.558     **\<0.001**   1.134     0.726‐1.77      0.581       0.372    0.218‐0.633    **\<0.001**   

  Tumor size          ≤2        ref.                                ref.                                    ref.                                 ref.                          

  2 \~ 5              1.221     0‐4.21E + 33   0.996       0.819    0‐3.383E + 40   0.997         3.467     0‐3.48E + 41    0.979       0.72     0‐9.72E + 46   0.995         

  \>5                 301.53    0‐3.54E + 31   0.867       560.63   0‐7.091E + 36   0.874         407.006   0‐1.40E + 42    0.897       554.50   0‐1.92E + 44   0.896         

  Unknown             0.566     0‐1.71E + 48   0.992       1.079    0‐1.529E + 84   0.999         1.331     0‐4.13E + 49    0.996       0.985    0‐8.1E + 107   1             
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The total CI and P value using Cox proportional hazards model and a bold type indicates significance. Abbreviations: HER2, human epidermal growth factor receptor 2; HRs, hazard ratios; CI, confidence interval.
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Propensity score matching analysis was also conducted in HR status‐based subgroup. Results showed that in the multivariable models, patients underwent RT showed significant prolonged OS (HR: 0.693, 95% CI: 0.484‐0.993, *P* = 0.046) in HoR + subgroup, while no significant differences were observed in breast cancer‐specific mortality. In addition, RT‐treated patients showed better BCSS (HR: 0.773, 95% CI: 0.612‐0.978, *P* = 0.032) in patients in the HoR‐ cohort, while significant difference was not observed in OS between HoR + and HoR‐ subgroups. The results were shown in Table [4](#cam42186-tbl-0004){ref-type="table"}.

###### 

Survival analysis in matched groups according to hormone receptors

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics     OS        BCSS                                                                                                                                                 
  ------------------- --------- --------------- -------------- -------- -------------- ------------- --------- --------------- --------------- -------- -------------- ------------- -------
  Race                White     ref.                                    ref.                                   ref.                                     ref.                          

  Black               1.461     1.134‐1.881     **0.003**      1.831    1.255‐2.672    **0.002**     1.449     1.113‐1.887     **0.006**       1.236    0.758‐2.017    0.395         

  Others              1.07      0.743‐1.54      0.716          0.605    0.314‐1.166    0.133         0.964     0.652‐1.427     0.856           0.611    0.315‐1.186    0.146         

                      Unknown   0.001           0‐2.01E + 22   0.807    0.962          0.132‐7.024   0.969     0.001           0‐3.987E + 22   0.809    0.014          0‐144063.4    0.603

  Age                 ≤40       ref.                                    ref.                                   ref.                                     ref.                          

  41‐45               0.972     0.783‐1.208     0.801          1.116    0.806‐1.545    0.508         0.942     0.75‐1.183      0.608           0.915    0.61‐1.374     0.669         

  Year of diagnosis   2010      ref.                                    ref.                                   ref.                                     ref.                          

  2010                0.959     0.745‐1.233     0.741          1.207    0.812‐1.796    0.353         0.955     0.735‐1.24      0.729           1.406    0.887‐2.23     0.147         

  2010                0.907     0.63‐1.306      0.6            1.365    0.804‐2.317    0.25          0.884     0.601‐1.3       0.53            0.968    0.484‐1.936    0.926         

  2010                0.727     0.283‐1.869     0.801          0.491    0.064‐3.751    0.493         0.674     0.235‐1.928     0.462           1.08     0.13‐8.99      0.943         

  Laterality          Left      ref.                                    ref.                                   ref.                                     ref.                          

  Right               1.072     0.863‐1.332     0.528          0.813    0.588‐1.125    0.853         1.001     0.798‐1.256     0.993           0.81     0.551‐1.189    0.281         

  Bilateral           0.001     0‐5.9E + 161    0.973          0        0              0.986         0.001     0‐2.1E + 166    0.973           0.019    0‐1.10E + 41   0.937         

  Unknown             29.58     3.74‐233.9      **0.001**      0        0              0.998         32.01     4.00‐256.13     **0.001**       0.015    0              0.993         

  Differen\           Grade I   ref.                                    ref.                                   ref.                                     ref.                          
  tiation                                                                                                                                                                            

  Grade II            3.078     0.413‐22.92     0.272          3070.0   0‐7.13E + 49   0.883         1186.90   0‐4.986E + 19   0.717           33.042   0‐1.212E + 9   0.694         

  Grade III           2.939     0.402‐21.50     0.288          5094.8   0‐1.18E + 50   0.875         1099.73   0‐4.616E + 19   0.72            104.50   0‐3.786E + 9   0.601         

  Grade IV            2.996     0.305‐29.04     0.21           0.532    0‐7.5E + 115   0.996         760.301   0‐3.272E + 19   0.734           67.21    0‐2.716E + 9   0.638         

  Unknown             3.722     0.477‐29.04     0.21           7028.0   0‐1.63E + 50   0.871         1355.86   0‐5.711E + 19   0.712           139.41   0‐5.142E + 9   0.579         

  Histologic          Duct      ref.                                    ref.                                   ref.                                     ref.                          

  Lobular             3.11      1.117‐8.654     **0.03**       0.586    0.229‐1.5      0.265         4.341     1.543‐12.22     **0.005**       0.392    0.091‐1.682    0.208         

  Duct\               1.912     0.971‐3.767     0.061          1.54     0.713‐3.324    0.271         2.091     1.065‐4.108     **0.032**       1.946    0.838‐4.522    0.121         
  &lobular                                                                                                                                                                           

  Others              0.966     0.624‐1.497     0.877          1.39     0.597‐3.234    0.445         1.042     0.658‐1.65      0.862           1.477    0.531‐4.111    0.455         

  T                   T1        ref.                                    ref.                                   ref.                                     ref.                          

  T2                  5458.55   0‐4.862E + 31   0.793          0.662    0.014‐31.08    0.834         5740.50   0‐8.171E + 32   0.8             1.25     0‐8.06E + 36   0.996         

  T3                  2.007     0.267‐15.07     0.498          0.957    0.035‐26.16    0.979         1.699     0.222‐13        0.61            0.019    0‐7.27E + 32   0.922         

  N                   N0        ref.                                    ref.                                   ref.                                     ref.                          

  N1                  1.652     1.257‐2.171     **\<0.001**    1.31     0.876‐1.935    0.188         1.744     1.307‐2.327     **\<0.001**     1.833    1.106‐3.038    **0.019**     

  N2                  3.215     2.272‐4.551     **\<0.001**    2.325    1.375‐3.938    **0.002**     3.438     2.393‐4.940     **\<0.001**     2.413    1.245‐4.676    **0.009**     

  N3                  5.574     3.98‐7.806      **\<0.001**    4.752    0.176‐128.4    0.354         6.211     4.378‐8.811     **\<0.001**     5.807    3.179‐10.61    **\<0.001**   

  Radiation           No        ref.                                    ref.                                   ref.                                     ref.                          

  Yes                 0.835     0.666‐1.046     0.116          0.693    0.484‐0.993    **0.046**     0.773     0.612‐0.978     **0.032**       0.744    0.499‐1.108    0.145         

  Tumor size          ≤2        ref.                                    ref.                                   ref.                                     ref.                          

  2 \~ 5              0         0‐2.77E + 24    0.806          2.414    0.052‐112.2    0.653         0         0‐4.349E + 25   0.609           1.931    0‐1.24E + 37   0.988         

  \>5                 1.365     0.182‐10.23     0.762          3.128    0.114‐85.74    0.5           1.7       0.223‐12.97     0.609           229.52   0‐8.96E + 36   0.894         

  Unknown             0         0‐1.7E + 102    0.949          7.752    0.176‐127.4    0.354         0         0‐7.22E + 104   0.951           539.97   0‐2.16E + 37   0.877         
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The total CI and P value using Cox proportional hazards model and a bold type indicates significance. Abbreviations: HoR, hormone receptors; HRs, hazard ratios; CI, confidence interval.
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3.4. Comparison of survival according to molecular subtypes {#cam42186-sec-0014}
-----------------------------------------------------------

The multivariate model was utilized to identify OS and BCSS of breast cancer patients according to molecular subtypes. Results showed that RT was a significant predictor for favorable OS in luminal‐A (HR: 0.696, 95% CI: 0.538‐0.902, *P* = 0.006), luminal‐B (HR: 0.385, 95% CI: 0.199‐0.744, *P* = 0.005), and HER2‐enriched patients (HR: 0.295, 95% CI: 0.138‐0.63, *P* = 0.002). However, no significant benefit of RT on survivals was observed in the triple‐negative cohort (*P* = 0.534, Table [5](#cam42186-tbl-0005){ref-type="table"}).

###### 

Comparison of overall survival (OS) according to breast cancer molecular subtypes

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics     Luminal‐A   Luminal‐B      HER2‐enriched   Triple negative                                                                                                                    
  ------------------- ----------- -------------- --------------- ----------------- -------------- ------------- ---------- -------------- -------------- ---------- --------------- --------------- -------
  Race                White       ref.                                             ref.                                    ref.                                     ref.                             

  Black               1.795       1.343‐2.4      **\<0.001**     1.677             0.786‐3.579    0.181         1.698      0.725‐3.98     0.223          1.263      0.97‐1.644      0.083           

  Others              0.375       0.209‐0.674    **0.001**       0.608             0.183‐2.016    0.416         2.331      1.022‐5.318    **0.044**      0.923      0.607‐1.403     0.708           

                      Unknown     0.855          0.21‐3.481      0.502             3.06           0.398‐23.52   0.282      0.001          0‐2.5E + 209   0.977      0.002           0‐4.393E + 11   0.708

  Age                 ≤40         ref.                                             ref.                                    ref.                                     ref.                             

  41‐45               1.057       0.82‐1.363     0.667           0.75              0.33‐1.705     0.492         1.307      0.683‐2.499    0.419          0.864      0.685‐1.090     0.218           

  Year of diagnosis   2010        ref.                                             ref.                                    ref.                                     ref.                             

  2010                1.305       0.959‐1.775    0.09            0.75              0.33‐1.705     0.492         0.702      0.321‐1.532    0.374          0.974      0.746‐1.272     0.847           

  2010                1.464       0.96‐2.233     0.077           1.002             0.293‐3.427    0.998         0.627      0.194‐2.026    0.435          0.953      0.65‐1.397      0.805           

  2010                1.26        0.427‐3.717    0.676           2.321             0.259‐15.01    0.376         0.945      0.104‐8.553    0.96           0.641      0.224‐1.834     0.407           

  Laterality          Left        ref.                                             ref.                                    ref.                                     ref.                             

  Right               0.828       0.645‐1.064    0.14            2.02              1.068‐3.824    0.031         1.4        0.712‐2.751    0.329          1.016      0.808‐1.278     0.891           

  Bilateral           ---                                        0.008             0‐8.1E + 111   0.971         ---                                      0.003      0‐8.454E + 87   0.957           

  Unknown             0           0              0.999           0.003             0              0.993         ---                                      23.141     2.873‐186.38    **0.003**       

  Differen\           Grade I     ref.                                             ref.                                    ref.                                     ref.                             
  tiation                                                                                                                                                                                           

  Grade II            1.086       0.645‐1.83     0.757           238.289           0‐2.37E + 12   0.641         666.716    0‐8.4e + 47    0.902          4.632      0.6‐35.767      0.142           

  Grade III           3.257       1.982‐5.351    **\<0.001**     257.683           0‐2.56E + 12   0.636         562.403    0‐7.07e + 47   0.905          3.534      0.467‐26.755    0.222           

  Grade IV            0           0‐1.2E + 123   0.951           1143.473          0‐1.24E + 13   0.55          0.424      0‐5.91E + 63   0.991          3.813      0.378‐38.478    0.256           

  Unknown             3.835       1.95‐7.542     **\<0.001**     553.323           0‐5.63E + 12   0.591         487.493    0‐6.18E + 47   0.907          5.398      0.661‐44.077    0.116           

  Histologic          Duct        ref.                                             ref.                                    ref.                                     ref.                             

  Lobular             0.525       0.286‐0.965    **0.038**       1.529             0.204‐11.48    0.68          0.004      0‐4.07E + 39   0.91           2.872      0.94‐8.772      0.064           

  Duct &lobular       1.291       0.772‐2.159    0.331           1.003             0.234‐4.289    0.997         0.632      0.077‐5.177    0.669          2.384      1.155‐4.92      **0.019**       

  Others              1.467       0.876‐2.456    0.145           1.468             0.343‐6.29     0.605         0.861      0.204‐3.639    0.839          0.941      0.592‐1.496     0.797           

  T                   T1          ref.                                             ref.                                    ref.                                     ref.                             

  T2                  0.416       0.007‐26.13    0.678           1.187             0‐3.23E + 80   0.999         0.733      0‐1.38E + 64   0.997          2689.963   0‐9.236E + 29   0.8             

  T3                  0.927       0.024‐35.21    0.967           0.003             0‐8.42E + 62   0.94          0.002      0‐5.17E + 48   0.917          4.38       0.482‐39.764    0.189           

  N                   N0          ref.                                             ref.                                    ref.                                     ref.                             

  N1                  1.31        0.968‐1.774    0.08            1.702             0.767‐3.779    0.191         0.921      0.369‐2.299    0.861          1.814      1.465‐2.411     **\<0.001**     

  N2                  1.576       1.012‐2.454    **0.044**       3.458             1.217‐9.821    0.02          3.293      1.259‐8.614    **0.015**      3.467      2.384‐5.041     **\<0.001**     

  N3                  4.038       2.682‐6.079    **\<0.001**     12.918            5.107‐32.67    **\<0.001**   7.688      2.94‐20.094    **\<0.001**    6.335      4.419‐9.083     **\<0.001**     

  Radiation           No          ref.                                             ref.                                    ref.                                     ref.                             

  Yes                 0.696       0.538‐0.902    **0.006**       0.385             0.199‐0.744    **0.005**     0.295      0.138‐0.63     **0.002**      0.927      0.73‐1.177      0.534           

  Tumor size          ≤2          ref.                                             ref.                                    ref.                                     ref.                             

  2 \~ 5              4.484       0.072‐279.2    0.477           1.16              0‐3.15E + 80   0.999         2.278      0‐4.29E + 64   0.991          0.001      0‐2.097E + 23   0.812           

  \>5                 3.84        0.101‐146.5    0.469           759.254           0‐2.14E + 68   0.931         1571.243   0‐4.31E + 54   0.903          0.673      0.075‐6.049     0.724           

  Unknown             3.888       0.102‐147.5    0.464           1.994             0‐8.2E + 168   0.997         1.732      0‐4.0E + 160   0.998          0.001      0               0.991           
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The total CI and P value using Cox proportional hazards model and a bold type indicates significance. Abbreviations: HRs, hazard ratios; CI, confidence interval.
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In the multivariate model for BCSS, RT was a significant independent prognostic predictor and correlated with prolonged survival in HER2‐enriched patients (HR: 0.328, 95% CI: 0.153‐0.702, *P* = 0.004). Notably, RT was associated with a slightly higher BCSS (HR: 0.464, 95% CI: 0.211‐1.020, *P* = 0.056) in the luminal‐B cohort but statistical significance was not reached. There was no significant difference in BCSS between RT‐treated patients and controlled patients in luminal‐A (*P* = 0.112) and triple‐negative patients (*P* = 0.250). Higher N stage was also an independent adverse prognostic factor for OS and BCSS in all breast cancer cohorts (all *P* \< 0.05). Black race was associated with worse OS (HR: 1.795, 95% CI: 1.341‐2.4, *P* \< 0.001) and BCSS (HR: 1.212, 95% CI: 01.212‐2.342, *P* = 0.002) in the luminal‐A cohort. Kaplan‐Meier curves of OS and BCSS for different breast cancer subgroups are shown in Figures [2](#cam42186-fig-0002){ref-type="fig"} and [3](#cam42186-fig-0003){ref-type="fig"}, respectively.

![Kaplan‐Meier curve of overall survival in patients with luminal A (A), luminal B (B), HER2‐enriched (C) and triple negative (D) early‐stage breast cancer](CAM4-8-2840-g002){#cam42186-fig-0002}

![Kaplan‐Meier curve of breast cancer‐specific survival in patients with luminal A (A), luminal B (B), HER2‐enriched (C) and triple negative (D) early‐stage breast cancer](CAM4-8-2840-g003){#cam42186-fig-0003}

3.5. Comparison of RT benefit according to the characteristics {#cam42186-sec-0015}
--------------------------------------------------------------

We conducted an exploratory subgroup analysis to identify potential benefit of RT in specific subgroups. The HRs and 95% confidence intervals comparing OS and BCSS according to the RT for several of characteristics were shown in Figure [4](#cam42186-fig-0004){ref-type="fig"}, and detailed statistics are listed in Supplementary Table [S1](#cam42186-sup-0001){ref-type="supplementary-material"}. Results showed that response to radiotherapy for patients varies according to different characteristics and factors (Table [6](#cam42186-tbl-0006){ref-type="table"}).

![Hazard ratio and 95% confidence interval for overall survival (A) and breast cancer‐specific survival (B) according to the receipt of radiotherapy in the subgroup of patients for each characteristic](CAM4-8-2840-g004){#cam42186-fig-0004}

###### 

Comparison of breast cancer‐specific survival (BCSS) according to breast cancer molecular subtypes

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics     Luminal‐A   Luminal‐B       HER2‐enriched   Triple negative                                                                                                                         
  ------------------- ----------- --------------- --------------- ----------------- ---------------- -------------- ------------ --------------- --------------- -------- --------------- --------------- -------
  Race                White       ref.                                              ref.                                         ref.                                     ref.                             

  Black               1.685       1.212‐2.342     **0.002**       0.728             0.214‐2.477      0.611          1.889        0.791‐4.510     0.152           1.234    0.936‐1.629     0.136           

  Others              0.423       0.229‐0.783     **0.006**       0.56              0.13‐2.414       0.437          2.434        1.054‐5.624     **0.037**       0.780    0.49‐1.241      0.294           

                      Unknown     1.125           0.275‐4.605     0.87              0.033            0‐5.147E + 7   0.753        0.001           0‐3.37E + 220   0.978    0.002           0‐6.107E + 11   0.710

  Age                 ≤40         ref.                                              ref.                                         ref.                                     ref.                             

  41‐45               0.907       0.681‐1.21      0.507           0.996             0.457‐2.168      0.992          1.458        0.746‐2.85      0.27            0.816    0.638‐1.043     0.105           

  Year of diagnosis   2010        ref.                                              ref.                                         ref.                                     ref.                             

  2010                1.395       0.989‐1.968     0.058           0.71              0.265‐1.901      0.496          0.80472697   0.36‐1.8        0.597           0.949    0.717‐1.255     0.711           

  2010                1.236       0.742‐2.058     0.416           0.47              0.054‐4.078      0.494          0.682115     0.208‐2.235     0.528           0.910    0.605‐1.368     0.649           

  2010                0.758       0.096‐5.963     0.792           0.018             0‐609481813      0.746          0.97835089   0.108‐8.894     0.984           0.545    0.163‐1.829     0.326           

  Laterality          Left        ref.                                              ref.                                         ref.                                     ref.                             

  Right               0.792       0.597‐1.05      0.105           2.076             0.94‐4.586       0.071          1.492        0.737‐3.022     0.266           0.941    0.738‐1.199     0.621           

  Bilateral           ---                                         0.004             0‐1.024E + 213   0.982          ---                                          0.003    0‐7.697E + 90   0.958           

  Unknown             0           0               0.996           0.083             0                0.999          ---                                          27.13    3.311‐222.234   **0.002**       

  Differen\           Grade I     ref.                                              ref.                                         ref.                                     ref.                             
  tiation                                                                                                                                                                                                 

  Grade II            1.58        0.737‐3.39      0.24            101.652           0‐1126736963     0.577          790.066375   0‐9.042E + 53   0.911           635.9    0‐1.17E + 12    0.553           

  Grade III           5.967       0.737‐3.39      0.24            77.579            0‐8.5667E + 8    0.588          639.936578   0‐7.309E + 53   0.914           473.1    0‐8.688E + 11   0.571           

  Grade IV            0.009       0‐4.003E + 17   0.837           454.593           0‐5724106803     0.463          0.43039011   0‐4.647E + 70   0.992           380.4    0‐7.302E + 11   0.586           

  Unknown             6.272       2.532‐15.537    **\<0.001**     0.244             0‐3.156E + 19    0.952          572.751272   0‐6.597E + 53   0.916           676.4    0‐1.252E + 12   0.549           

  Histologic          Duct        ref.                                              ref.                                         ref.                                     ref.                             

  Lobular             0.558       0.276‐1.129     0.105           1.811             0.238‐13.749     0.566          0.004        0‐2.095E + 40   0.839           4.094    1.304‐12.86     **0.016**       

  Duct &lobular       1.45        0.834‐2.521     0.188           1.24              0.274‐5.617      0.78           0.735        0.088‐6.161     0.777           2.821    1.382‐5.75      **0.004**       

  Others              1.19        0.624‐2.27      0.597           1.698             0.217‐13.285     0.614          0.953        0.225‐4.045     0.948           1.034    0.633‐1.688     0.894           

  T                   T1          ref.                                              ref.                                         ref.                                     ref.                             

  T2                  299.262     0‐2.88E + 26    0.84            284.081           0‐2.002E + 100   0.961          0.68569615   0‐1.022E + 74   0.997           4456.1   0‐1.147E + 33   0.835           

  T3                  1.075       0.02‐56.525     0.972           0.97              0‐2.986E + 64    1              0.00167168   0‐1.158E + 60   0.931           3.084    0.325‐29.237    0.326           

  N                   N0          ref.                                              ref.                                         ref.                                     ref.                             

  N1                  1.448       1.021‐2.053     **0.038**       1.142             0.382‐3.413      0.812          0.92105716   0.361‐2.352     0.863           1.941    1.435‐2.625     **\<0.001**     

  N2                  1.79        1.101‐2.911     **0.019**       3.561             1.023‐12.391     **0.046**      2.75321208   0.994‐7.623     0.051           3.844    2.603‐5.678     **\<0.001**     

  N3                  4.575       2.921‐7.168     **\<0.001**     19.503            6.69‐56.856      **\<0.001**    7.41758298   2.785‐19.754    **\<0.001**     7.491    5.141‐10.915    **\<0.001**     

  Radiation           No          ref.                                              ref.                                         ref.                                     ref.                             

  Yes                 0.789       0.589‐1.056     0.112           0.464             0.211‐1.020      0.056          0.328        0.153‐0.702     **0.004**       0.864    0.674‐1.109     0.250           

  Tumor size          ≤2          ref.                                              ref.                                         ref.                                     ref.                             

  2 \~ 5              0.007       0‐7.039E + 21   0.861           0.005             0‐3.232E + 95    0.963          2.45432835   0‐3.649E + 74   0.992           0.001    0‐8.679E + 26   0.847           

  \>5                 3.875       0.073‐204.76    0.503           3.058             0‐9.404E + 64    0.988          1919.59015   0‐1.33E + 66    0.918           1.001    0.107‐9.357     0.999           

  Unknown             4.385       0.084‐229.85    0.464           0.165             0‐1.998E + 137   0.991          1.30846106   0‐9.98E + 176   0.999           0.002    0               0.993           
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The total CI and P value using Cox proportional hazards model and a bold type indicates significance. Abbreviations: HRs, hazard ratios; CI, confidence interval.

John Wiley & Sons, Ltd

Black patients showed prolonged OS (HR: 0.742 vs 1.058 and 1.229, all *P* \> 0.05) and BCSS (HR: 0.749 vs 1.11 and 1.168, all *P* \> 0.05) compared to white patients and others with RT treatment. Patients aged 41‐45 showed better benefit from RT on OS (HR: 0.751 vs 1.268, *P* = 0.014 and 0.031, respectively) and BCSS (HR: 0.752 vs 1.329, *P* = 0.029 and 0.016, respectively) compared to those younger than 40. In addition, breast cancer patients with grade I in differentiation degree was associated with prolonged OS, though not significant in BCSS after RT receipt. Patients diagnosed with I, IIA and IIIC showed better OS (HR: 0.469, 0.616 and 0.434, *P* = 0.002, 0.005 and \<0.001, respectively) and BCSS (HR: 0.439, 0.634 and 0.411, *P* = 0.009, 0.016 and \<0.001, respectively) received RT, while IIB and IIIA breast cancer showed no survival benefit from radiation treatment. A significantly prolonged OS was observed when RT was given to patients with breast tumor size less than 2 cm (HR: 0.639, *P* = 0.008), as well as larger than 5 cm (HR: 0.674, *P* = 0.015). Patients with tumor size larger than 5 cm could also benefit from RT in breast cancer‐specific survival (HR 0.679, *P* = 0.023).

4. DISCUSSION {#cam42186-sec-0016}
=============

Although RT has been accepted as one of the most significant treatments for breast cancer patients, the impact of molecular subtypes on RT response in early‐stage breast cancer patients has not been exactly elucidated in previous literatures.[20](#cam42186-bib-0020){ref-type="ref"}, [21](#cam42186-bib-0021){ref-type="ref"}, [22](#cam42186-bib-0022){ref-type="ref"}, [23](#cam42186-bib-0023){ref-type="ref"} To the best of our knowledge, this is the first population‐based retrospective study aimed to address the prognostic role of RT and its impact on OS and BCSS in young early‐stage breast cancer female patients according to molecular subtypes.

We carried out the Kaplan‐Meier analysis and found that RT is a significant predictor in the entire young early‐stage breast cancer cohort. Furthermore, we attempted to investigate the potential subgroups that would benefit from RT. Significant prolonged OS and BCSS were observed in RT‐treated HER2 + breast cancer patients compared to those with HER2‐ after demographic and clinicopathologic characteristics adjustment. However, patients treated with radiotherapy presented a significantly better OS in HoR + cohort, while a prolonged BCSS in the HoR‐subgroup. Multivariate analysis showed that relative to triple‐negative subtype, RT‐treated patients with luminal‐A, luminal‐B, or HER2‐overexpressing had a significant prolonged OS. HER2‐overexpressing breast cancer patients subjected to RT was also correlated with better BCSS.

Studies had investigated different effects of adjuvant RT according to tumor subtype in mastectomy cases. Marianne et al reported 1 000 high‐risk breast cancer patients received postmastectomy radiotherapy (PMRT) and demonstrated that HoR, HER2 status, and the constructed subtypes may be predictive of locoregional recurrence and survival. Results showed a significant improved OS among patients after PMRT characterized by good prognostic markers such as HoR + and HER2‐ patients.[24](#cam42186-bib-0024){ref-type="ref"} Another study demonstrated that triple‐negative patients had the highest risk of locoregional recurrence and the least benefit from PMRT, while the greatest effect was seen among luminal‐A patients.[25](#cam42186-bib-0025){ref-type="ref"} These researches indicated that the largest RT benefit was shown in luminal‐type breast cancer.

Luminal‐A and luminal‐B patients subjected to RT showed improved OS in our study, which was in consistent with the previous discoveries. We also revealed that HER2‐enriched patients showed the mostly benefit from radiation therapy. While a preclinical analysis revealed that no significant OS improvement after PMRT was found in HER2‐enriched high‐risk breast cancer patients,[24](#cam42186-bib-0024){ref-type="ref"} HER2 + was shown as a predictor for favorable survival compared with the HER2‐ in RT‐treated patients in our study. Furthermore, our results showed that RT was not an independent significant factor for BCSS in luminal‐A and luminal‐B breast cancer patients, with statistical significance not reached (*P* = 0.112 and 0.056, respectively). This discrepancy might be due to the following factors: (a) different inclusion criteria. Patients recruited in the previous study were presented with more malignancy‐associated properties, while patients were restricted to young early‐stage breast cancer in our study; (b) different therapy strategies. All their patients received a total mastectomy and a partial axillary dissection while surgery was given randomly in our study; (c) different types of radiotherapy. Apart from PMRT they performed, the type of RT in our study also included radioactive implant, isotopes. The sequence of RT with surgery also varies; (d) heterogeneity of patient\'s resources; and (e) the follow‐up period in our study was not long enough.

RT showed no significant prolonged OS and BCSS among patients with triple‐negative breast cancer (TNBC) in this study. Similar to our results, several of previous articles discovered that there might exist radio‐resistance in TNBC patients, which has not been confirmed though. A meta‐analysis performed by Kyndi et al showed that the local recurrence rates in triple‐negative patients did not decrease as much as those with luminal type, which indicated the relatively low radio‐sensitivity of TNBC cells.[24](#cam42186-bib-0024){ref-type="ref"} According to a research from The Cancer Genome Atlas, the radioresistance might be due to depletion or overexpression of several genes, such as the epidermal growth factor receptor (EGFR). In TNBC cells, EGFR overexpression could enhance proliferation and DNA damage response, as well as reduce apoptosis via PI3K‐Akt signaling pathway, and led to increased radioresistance.[26](#cam42186-bib-0026){ref-type="ref"} Other similar regulations including MELK overexpression or CDC27 depletion also contributed to the radio‐resistance of TNBC cells in the same way. However, all of these do not mean that RT in TNBC is not important. Studies clarified that postoperative radiotherapy for TNBC patients could reduce the local recurrence rate, especially for the patients with ≥4 positive axillary lymph nodes.[15](#cam42186-bib-0015){ref-type="ref"}, [27](#cam42186-bib-0027){ref-type="ref"}, [28](#cam42186-bib-0028){ref-type="ref"} In addition, we could discover and target specific potential biomarkers to regulate the proliferation and radio‐sensitivity of TNBC cells.

The underlying mechanism of how molecular subtypes affect RT benefit in breast cancer patients remains uncertain, further studies are still needed to elucidate potential signaling pathways. The results could help predicting tumor tissue response to RT, thus improve evidence‐based patients care and prolong patient\'s survival by adjusting therapy strategies. There also exist limitations in our study. First of all, we only included patients after 2010 since the HER2 status was not available before, which largely limited our follow‐up period. Secondly, some important information including Ki‐67 level, chemotherapy and endocrine therapy strategies were not available, this may result in potential bias. Lastly, the retrospective nature is an unavoidable weakness, thus larger perspective researches are needed to confirm the results. This limitation highlights the need for large designed prospective clinical researches to guide radiotherapy strategy in different IHC‐based subtypes of breast cancer, as well as achieve a longer follow‐up time to verify and extend our findings. In addition, therapeutic evaluation with systemic treatments including chemotherapy, hormone therapy and monoclonal target therapy should be added in further studies to understand RT benefit and the underlying mechanisms better. Despite the limitations, our study has several of strengths. No previous study has focused on the survival benefit in young early‐stage breast cancer for RT, though many have shown improvement in local control and local‐regional recurrence with postoperative radiation.[27](#cam42186-bib-0027){ref-type="ref"}, [28](#cam42186-bib-0028){ref-type="ref"} This is the first study comparing the RT benefit in young women with localized early stage breast cancer according to molecular subtypes via PSM to minimize potential bias. In addition, another major strength of this study is the large size of the patient cohort, which allowed us to provide contemporary information to the significance and benefit of RT in young early‐stage breast cancer patients according to different molecular subtypes‐that reflect the circumstances in the real world.

Based on our results, RT tended to have survival benefit in luminal‐A, luminal‐B and especially HER2‐enriched young early‐stage breast cancer female patients. In addition, HER2 was significant favorable factor for RT benefit in breast cancer patient. The results could help predicting RT response and improve patient\'s survival by adjusting treatment strategies for individuals. Further studies are needed to identify underlying mechanisms of the difference RT sensitivity in breast cancer molecular subtypes.
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